glp-1 receptor agonists in idiopathic intracranial hypertension Treatment with is associated with significant weight loss and favorable headache outcomes | The Journal of Headache and Pain IIH (Idiopathic Intracranial Hypertension): Symptoms,

Type 3 cytokines IL-17A and IL-22 drive TGF--dependent liver fibrosis

Sustainability Concerns : The requirement for potentially lifelong therapy, combined with rapid weight regain upon discontinuation, raises questions about long-term sustainability and practical implementation

Abstract Background Obesity has emerged as a pressing global health challenge, and therapies based on glucagon-like Peptide 1 receptor agonists (GLP-1RAs) have transformed its management

4), which did not withstand the adjustment for weight loss (Supplementary Table 2)

Compared with the treatment of short-acting GLP-1R agonists, LIR has a greater improvement in lowering glycated hemoglobin and fasting blood glucose

[DOI] [PubMed] [Google Scholar] 66.Krajnc N, Itariu B, Macher S, Marik W, Harreiter J, Michl M, et al